A Registry for People With Lung Cancer | Clinical Trial

Key information

Conditions

Lung Cancer Lung Cancer Stage I Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Health Network (Data Collection Only), Toronto, Ontario, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18 years
Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology

Exclusion criteria

Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
History of chemotherapy or radiation therapy for a previous lung cancer
Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
Carcinoid tumors
History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
Actively receiving treatment for other malignancies
Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.

Multi-segmental resection from the same lobe is not a criterion for exclusion.

Treatment and study plan

Patient-Reported Outcomes Measurement Information System

Other

Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)

Other names: PROMIS

Primary outcomes

Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.

Time frame: 3 years

DFS is measured from the date of surgery to the date of recurrence or death
Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.

Time frame: 5 years

DFS is measured from the date of surgery to the date of recurrence or death

Study contacts

Contact information is provided by the study sponsor or research team.

Bernard Park, MD

CONTACT

[email protected]

646-888-3346

David Jones, MD

CONTACT

[email protected]

212-639-6428

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Official study title

Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108

Important dates

Study start: 2024
Primary completion: 2029
Study completion: 2029
First posted: May 22, 2024
Registry last updated: Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting